Type 1 diabetes patients who were on teplizumab, an experimental treatment, were able to maintain their insulin production rates for two years, longer than patients on most other diabetes medications, according to data from a Phase II study published in Diabetes. However, about half of patients did not benefit from the drug. Researchers said patients who saw the most benefit were those who still had good glucose control and moderate insulin requirements at the start of the study.

Related Summaries